Alto Neuroscience (NYSE:ANRO – Get Free Report) announced its earnings results on Wednesday. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.24), FiscalAI reports.
Here are the key takeaways from Alto Neuroscience’s conference call:
- Alto emphasized that its lead program ALTO-207 has shown a potentially differentiated efficacy signal in treatment-resistant depression by directly stimulating dopamine receptors, with the company positioning it as a potential best-in-class approach if tolerability issues are solved.
- The company highlighted encouraging data from prior studies, including the PAX-D trial and an earlier phase IIa study, where pramipexole-based treatment showed large effect sizes and durable benefit over time, though nausea and vomiting remained the key limitation.
- Alto said it has launched a 178-patient phase IIb trial of ALTO-207 in Q2, using a fixed-dose combination of pramipexole and ondansetron designed to improve tolerability and enable faster titration, with top-line results expected in the second half of next year.
- Management stated that the company’s current cash runway is expected to fund multiple late-stage programs, including ALTO-207 through a planned phase III path, with cash reportedly lasting through 2029.
- Beyond ALTO-207, Alto pointed to two other biomarker-guided programs, ALTO-300 in depression and ALTO-100 in bipolar depression, as additional near-term clinical catalysts with the potential to address large unmet needs.
Alto Neuroscience Stock Performance
Shares of NYSE:ANRO traded down $1.69 on Wednesday, hitting $22.94. 416,747 shares of the company were exchanged, compared to its average volume of 284,960. The company’s 50 day moving average price is $23.13 and its two-hundred day moving average price is $18.38. The company has a debt-to-equity ratio of 0.12, a quick ratio of 15.69 and a current ratio of 15.69. Alto Neuroscience has a one year low of $2.15 and a one year high of $28.44.
Analyst Upgrades and Downgrades
Read Our Latest Stock Analysis on Alto Neuroscience
Hedge Funds Weigh In On Alto Neuroscience
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd raised its stake in shares of Alto Neuroscience by 32.2% in the 4th quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock valued at $371,000 after buying an additional 5,078 shares in the last quarter. Ikarian Capital LLC boosted its stake in shares of Alto Neuroscience by 368.2% in the 4th quarter. Ikarian Capital LLC now owns 515,000 shares of the company’s stock valued at $9,167,000 after purchasing an additional 405,000 shares in the last quarter. Vestal Point Capital LP grew its holdings in shares of Alto Neuroscience by 161.6% in the 4th quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock worth $44,233,000 after purchasing an additional 1,535,000 shares during the last quarter. Wellington Management Group LLP bought a new stake in shares of Alto Neuroscience in the 4th quarter worth about $1,228,000. Finally, Millennium Management LLC increased its position in shares of Alto Neuroscience by 99.5% during the 4th quarter. Millennium Management LLC now owns 629,985 shares of the company’s stock worth $11,214,000 after purchasing an additional 314,227 shares in the last quarter.
Alto Neuroscience Company Profile
Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.
Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.
Featured Articles
- Five stocks we like better than Alto Neuroscience
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
